Indication
Treatment-Resistant
9 clinical trials
10 products
3 drugs
Clinical trial
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant DepressionStatus: Completed, Estimated PCD: 2024-01-31
Product
PlaceboProduct
EsketamineClinical trial
Phase 2a Multicenter Randomized Double-Blind Placebo-Controlled Study to Assess the Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing of REL-1017 as Adjunctive Therapy in the Treatment of Pts Diagnosed With MDDStatus: Completed, Estimated PCD: 2019-07-30
Product
REL-1017Clinical trial
OSU6162 as add-on in SSRI/SNRI-resistant Depression (ODEN): a Double-blind, Placebo-controlled Evaluation of Efficacy and SafetyStatus: Recruiting, Estimated PCD: 2026-05-31
Product
OSU6162Clinical trial
A Safe Ketamine-Based Therapy for Treatment Resistant DepressionStatus: Completed, Estimated PCD: 2014-06-06
Drug
KetamineProduct
ClonidineDrug
placeboClinical trial
Does the IMPase Inhibitor, Ebselen, Affect Emotional Processing and Brain Myo-inositol in Treatment-resistant Depression?Status: Recruiting, Estimated PCD: 2024-05-31
Product
EbselenClinical trial
Synaptic Imaging and Brain Network Activity Following Ketamine in Treatment Resistant DepressionStatus: Recruiting, Estimated PCD: 2023-08-31
Product
MidazolamDrug
VarlilumabClinical trial
An Open-Label, Single-Arm Clinical Trial Evaluating the Safety and Efficacy of Amisulpride in Treating Patients With Schizophrenia and Schizoaffective Disorder Who Have Treatment-Resistant Positive SymptomsStatus: Not yet recruiting, Estimated PCD: 2025-11-01
Product
AmisulprideClinical trial
Investigating Glutamate and Opioid Mechanisms of Antidepressant Response to KetamineStatus: Completed, Estimated PCD: 2023-02-13
Product
NaltrexoneClinical trial
Dopaminergic Dysfunction in Late-Life DepressionStatus: Recruiting, Estimated PCD: 2025-04-30
Product
L-Dopa